RT Journal Article
SR Electronic
T1 Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.14.24302840
DO 10.1101/2024.02.14.24302840
A1 Makunts, Tigran
A1 Grabska, Siranuysh
A1 Grabski, Hovakim
A1 Abagyan, Ruben
YR 2024
UL http://medrxiv.org/content/early/2024/02/15/2024.02.14.24302840.abstract
AB Therapeutic antibodies designed to target immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4 have been applied in the treatment of various tumor types, including small and non-small cell lung cancers, melanoma, renal cell carcinoma, and others. These treatments combat cancers by reactivating CD8 cytotoxic T-cells. Nevertheless, this unique targeted mode of action was found to be associated with a broader range of immune-related adverse events, irAEs, affecting multiple physiological systems. Depending on their severity, these irAEs often necessitate the suspension or discontinuation of treatment and, in rare instances, may lead to fatal consequences. In this study we investigated over eighty thousand adverse event reports of irAEs in patients treated with PD-1, PD-L1, and CTLA-4 inhibitors. FDA Adverse Event Reporting System MedWatch submissions were used as the data source. These therapeutics included pembrolizumab, nivolumab, cemiplimab, avelumab, durvalumab, atezolizumab, and ipilimumab. The data analysis of these reports revealed a statistically significant association of immune related adverse events, including serious and life-threatening events in patients who experienced infectious disease during treatment. Additionally, the association trend was preserved across all the three classes of checkpoint inhibitors and each of the seven individual therapeutic agent cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded in part by NIH R35GM131881. The study was in part funded by FAST Armenia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analyzed for this study can be found in the FAERS database. For online access to FAERS/AERS datasets, please refer to the following link: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html The FDA Medical Queries tables were made available online in September 2022 and may be accessed at: https://downloads.regulations.gov/FDA-2022-N-1961-0001/attachment_1.xlsm https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html AEadverse eventAERSadverse event reporting systemADautoimmune diseaseCIconfidence intervalCTLA-4cytotoxic T-lymphocyte–associated antigen 4FDAFood and Drug AdministrationFAERSFDA Adverse Event Reporting SystemFMQsFDA medical queriesICIimmune checkpoint inhibitorsirAEimmune-related adverse eventsPD-1programmed cell death protein 1PD-L1programmed cell death protein 1 ligandRORReporting odds ratiosPTPreferred term